Eye Care Contract Manufacturing Red Flags U.S. Buyers Should Catch Early

Eye care products—especially ophthalmic solutions and sterile ointments—come with some of the strictest manufacturing requirements in the personal care industry. A misstep in sourcing can lead to shipment holds, costly reformulations, or even a product recall. U.S. buyers need to spot red flags early in the vetting process to protect their brand and their timeline.

Regulatory & Compliance Red Flags

In the U.S., most over‑the‑counter eye drops, artificial tears, and eye washes are regulated as OTC drugs under FDA monographs. A manufacturer that struggles to demonstrate full compliance should be considered a risk.

• No FDA establishment registration or drug listing – The facility must be registered with the FDA, and the product must be listed. Ask for the registration number and verify it online.
• Unfamiliarity with the OTC eye drug monograph – For example, not knowing the allowed active ingredients, maximum concentrations, or labeling requirements for ophthalmic demulcents, astringents, or vasoconstrictors.
• Missing or incomplete Drug Master File (DMF) – A Type III DMF for packaging or a Type II DMF for active pharmaceutical ingredients (APIs) supports your own regulatory filings. If the factory cannot provide a DMF letter or access, it’s a warning sign.
• No track record of FDA inspections – A multi‑year gap without an FDA inspection (or recent Warning Letters/Import Alerts) should prompt deeper due diligence.

Sterility & Manufacturing Environment Red Flags

Ophthalmic products must be sterile. The absence of a robust sterility assurance program is a non‑negotiable red flag.

• Inadequate cleanroom classification – Aseptic filling of eye drops requires at least ISO Class 5 (Class 100) in the filling area. Verify the manufacturer operates under ISO 14644 standards and provides environmental monitoring data.
• No terminal sterilization or aseptic validation – Whether using moist heat, filtration, or aseptic processing, the method must be validated. Ask for sterilizing filter integrity test logs and media fill performance reports.
• Poor personnel and gowning protocols – A lack of documented gowning qualification or no airflow visualization (smoke studies) in the filling zone suggests contamination risk.
• Open‑product handling outside critical zones – If any step (cap feeding, filling needle adjustment) occurs in a lower‑grade area, sterility assurance is compromised.

Formulation & Ingredient Sourcing Red Flags

Eye‑tissue compatibility and preservative choice are delicate. Inexperienced blending or unvetted raw materials can cause ocular toxicity or instability.

• Using unapproved eye‑care preservatives – Certain preservatives (e.g., benzalkonium chloride) have established concentration limits. A manufacturer proposing non‑standard preservatives without robust ocular toxicity data is a risk.
• Lack of source qualification for ophthalmic‑grade excipients – Excipients like hypromellose, carboxymethylcellulose sodium, or glycerin must meet high purity standards. Request certificates of analysis that specifically state “ophthalmic grade” or compliance with USP/NF monographs.
• No preservative efficacy testing (PET) plans – Even with known preservatives, antimicrobial effectiveness testing per USP is mandatory. A factory that cannot show a PET study protocol or historical data is behind.
• Undisclosed changes in API or excipient suppliers – Red flag if the manufacturer cannot guarantee supplier change control with advance notice and re‑validation.

Quality Control & Testing Red Flags

Testing for eye care goes beyond standard cosmetic parameters. Missing or superficial test plans indicate a manufacturer that doesn’t understand the category.

Communication & Documentation Red Flags

Even technically capable manufacturers can fail through poor transparency. These red flags often emerge before a purchase order is signed.

• Unwillingness to share full batch records – If they offer only a “summary,” you lose visibility into process deviations and raw material traceability.
• No dedicated project manager for U.S. accounts – Slow, poorly translated answers can delay label review and regulatory submissions.
• Vague change control policy – Without a written commitment to notify you before changing any component, process, or test method, you risk unexpected validation costs.
• Poor audit history or resistance to on‑site audits – A factory that deflects audit requests or cannot provide a recent third‑party cGMP audit report (e.g., from an FDA‑recognized body) is a serious concern.

Frequently Asked Questions

What is the single most dangerous red flag?

An inability to demonstrate sterility assurance through validated processes, environmental monitoring data, and final product sterility testing. Sterility failures can lead to blindness‑risk recalls and permanent brand damage.

How can I quickly verify a manufacturer’s FDA status?

Search the FDA Establishment Registration & Device/Product Listing database using the firm’s name or registration number. Also check the FDA Warning Letters and Import Alert databases for recent entries.

Do all eye drop bottles need to pass extractables/leachables testing?

Yes. Even if the plastic components are FDA‑compliant, the interaction between the formulation and the container‑closure system must be evaluated. A proper study protects against unexpected leachables that could irritate eyes or degrade the active ingredient.

What if the contract manufacturer is ISO 13485 certified but has no drug cGMP experience?

ISO 13485 applies to medical devices, not OTC drug manufacturing. Eye drops are drugs; the facility must comply with 21 CFR Parts 210/211 and the OTC monograph. Medical device experience alone does not satisfy drug sterility and stability requirements.

Can I save time by skipping a pilot stability batch?

Not without risk. A pilot stability batch under ICH conditions provides critical early data on preservative efficacy, pH drift, and particulate formation. Skipping it can lead to a failed commercial lot that sets your launch back by months.

Identifying these red flags early can save a U.S. buyer from regulatory headaches and lost inventory. At Laeyo, we help brands navigate ophthalmic contract manufacturing with transparency, validated sterile filling, and a hands‑on approach to compliance. Request a Quote to start a conversation about your eye care project.

Hi, I'm Alex Zong, hope you like this blog post.

With more than 20 years of experience in OEM/ODM/Private Label Cosmetics, I'd love to share valuable knowledge related to cosmetics & skincare products from a top-tier Chinese supplier's perspective.